Tuesday, May 22, 2018
News: Page (1) of 1 - 06/18/12 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
FDA focuses on toxic side effects with Onyx drug
FDA review of Onyx Pharmaceuticals cancer drug focuses on toxic side effects
By The Associated Press

WASHINGTON (AP) ' Federal health regulators say the toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh the drug's benefits for patients with a type of blood cancer.

The Food and Drug Administration warned that patients taking the drug carfilzomib in company studies had a high rate heart and lung side effects, some which were fatal. The FDA posted its review of the drug ahead of a Wednesday meeting of its cancer drugs panel.

Onyx has asked the FDA to approve carfilzomib as a treatment for patients with advanced forms of multiple myeloma whose disease has spread despite treatment with other drugs.

Onyx shares fell almost 5 percent in premarket trading.

Multiple myeloma affects plasma cells in bone marrow. Over 50,000 people have the disease in the U.S., and about 20,000 new cases are diagnosed every year.

Page: 1


Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines